Hemotune is a developer of blood‑purification technology based on nano magnetic beads. The company has built a bead‑based blood‑purification platform intended for treatment of human diseases. Hemotune recently completed a CHF14 million Series B financing. The round was led by Belmondo, with existing investors VP Venture Partners, HEMEX, OCCIDENT and Zürcher Kantonalbank continuing to participate and EFI joining the round. Proceeds from the financing will be used to advance development of the company’s HemoSystem, described as a breakthrough blood‑purification platform based on nano‑engineered magnetic beads. No operating metrics, founding year, or location were provided in the article. Hemotune’s core product, HemoSystem, is a blood purification platform that mixes nanoengineered magnetic beads directly with patients’ blood in a dialysis-like machine and removes beads and bound targets via a magnetic filter before recirculation. The company says the system offers much higher efficiency and precision compared with existing methods. Its first therapy under development is designed to restore adequate immune response in sepsis-associated immunosuppression. Hemotune intends to use the recent funding to complete preclinical development of HemoSystem and to prepare a clinical trial in sepsis, its lead indication. The company highlights sepsis as an underserved global health issue that leads to around 11 million deaths annually. Hemotune was founded in 2017 as a spin-off from ETH Zurich and is being accelerated by Wyss Zurich. The company closed a CHF 7.25 million Series B1 to support these development and clinical-preparation efforts. Hemotune AG is a spin‑off from ETH Zurich (founded 2017) developing HemoSystem, a blood purification platform that mixes nanoengineered magnetic beads directly with patient blood in a dialysis‑like machine. The beads are roughly 300 times smaller than a red blood cell and are coated with selective binding agents to capture disease‑related compounds. While blood flows through a magnetic filter, beads and bound targets are removed before recirculation, with the aim of removing substances that play key roles in immune response and sepsis. With the Series A close hemotune will accelerate preclinical development of HemoSystem and pursue first launches in Europe. The company is incubated at Wyss Zurich and is positioning the technology for septic shock and other indications, with potential relevance to COVID‑19. Hemotune has built industry partnerships to support geographic expansion, notably with Korean partner GCMS for Asian market entry. The company has raised more than CHF 10 million in total since incorporation.

Total raised

$29M

Funding rounds

3

Latest round

Series B

Latest activity

Mar 2024